Is diabetes still a compelling indication for renin-angiotensin-aldosterone system inhibitors?

REFERENCES

1. ↵
   1. Momoniat T,
   2. Ilyas D,
   3. Bhandari S

   . ACE inhibitors and ARBs: Managing potassium and renal function. Cleve Clin J Med 2019; 86(9):601–607. doi:10.3949/ccjm.86a.18024

   OpenUrlAbstract/FREE Full Text
2. ↵
   1. Bangalore S,
   2. Fakheri R,
   3. Toklu B,
   4. Messerli FH

   . Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials. BMJ 2016; 352:i438. doi:10.1136/bmj.i438

   OpenUrlAbstract/FREE Full Text
3. ↵
   1. de Boer IH,
   2. Bangalore S,
   3. Benetos A,
   4. et al

   . Diabetes and hypertension: a position statement by the American Diabetes Association. Diabetes Care 2017; 40(9):1273–1284. doi:10.2337/dci17-0026

   OpenUrlFREE Full Text
4. ↵
   1. Williams B,
   2. Mancia G,
   3. Spiering W,
   4. et al

   . 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J 2018; 39(33):3021–3104. doi:10.1093/eurheartj/ehy339

   OpenUrlCrossRefPubMed
5. ↵
   1. James PA,
   2. Oparil S,
   3. Carter BL,
   4. et al

   . 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311(5):507–520. doi:10.1001/jama.2013.284427

   OpenUrlCrossRefPubMed